EBMT: A Tri-specific Killer Engager (TriKE®) against B7-H3 enhances NK cell mediated killing of multiple myeloma

March 22, 2022

ESMO Targeted Anticancer Therapies Congress: Driving NK cell immunotherapy against NSCLC, in the context of hypoxia, using Tri-specific Killer Engager (TriKE®)

March 9, 2022

B. Riley Oncology Conference Call Webcast - Replay

January 26, 2022

ESMO I/O: Novel B7-H3 Targeting Dual Nanobody NK Cell Engagers Display Robust Activity Against a Broad Spectrum of Solid and Hematologic Malignancies.

December 8, 2021

GT Biopharma Management Update Conference Call Webcast – Replay

November 30, 2021

Dr. Jeff Miller ESMO Congress 2021 Presentation

September 17, 2021

Second Quarter Financial Results & Business Update (8/13/21 registration)

August 6, 2021

The Raymond James Human Health Innovation Conference June 2021- REPLAY

1-7-21 Investor Update

January 7, 2021

GTB-3550 TriKE™ - Target Directed Serial Killing of AML Cancer Cell by NK Cells

January 7, 2021